Altre lingue Replimune Group, Inc.

Azioni

REPL

US76029N1063

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 08/07/2024			Variaz. 5gg	Var. 1 gen.
8,44 ^USD	+4,07%		-9,83%	+0,12%

13/06	Replimune Group firma un accordo PIPE da 100 milioni di dollari con investitori istituzionali	MT
11/06	Transcript : Replimune Group, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index	24/06
Replimune Group Signs $100 Million PIPE Deal with Institutional Investors	13/06
Replimune Announces $100 Million Private Placement Financing	13/06
Replimune : Corporate Presentation June 2024	12/06
Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding	12/06
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	07/06
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	06/06
Sector Update: Health Care	06/06
Replimune Shares Rise as Study Data on Melanoma Treatment Improves	06/06
Replimune : Primary Analysis of the IGNYTE Registrational Cohort Presentation June 2024	06/06
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma	06/06
Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma	06/06
Replimune : IGNYTE Oral Presentation at ASCO 2024	03/06
Replimune : RP2 Uveal Melanoma Oral Presentation at ASCO 2024	03/06
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	03/06
Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology Annual Meeting	03/06
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	16/05
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update	16/05
Replimune : Corporate Presentation May 2024	07/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Replimune Group, Inc.

Azioni

REPL

US76029N1063

Altre lingue

Filtri